Understanding ANA Blood Tests: Autoantibodies, Patterns & Clinical Significance
Antinuclear antibodies (ANA) are autoantibodies targeting nuclear components. They are a hallmark of systemic autoimmune diseases but also occur in healthy individuals and other conditions.
What ANA Detects
ANA testing (typically immunofluorescence assay - IFA on HEp-2 cells) identifies antibodies against:
- DNA (dsDNA, ssDNA)
- Histones
- Ribonucleoproteins (Sm, RNP, Ro/SSA, La/SSB)
- Centromere proteins
- Nucleolar proteins (Scl-70, PM-Scl)
- Nuclear envelope (lamins, pore complexes)
Interpretation Framework
Titer (Dilution)
- Low positive (1:40-1:80): Common in healthy (5-20%); low specificity
- Moderate (1:160-1:320): More clinically significant
- High (≥1:640): Strongly suggests autoimmune disease
Pattern (IFA)
| Pattern | Associated Antigens | Clinical Associations |
|---|---|---|
| Homogeneous (diffuse) | dsDNA, histones | SLE, drug-induced lupus |
| Speckled | Sm, RNP, Ro, La | SLE, Sjögren's, MCTD, scleroderma |
| Centromere | CENP-A, -B | Limited scleroderma (CREST) |
| Nucleolar | Scl-70, PM-Scl, RNA pol I/III | Diffuse scleroderma, PM/DM overlap |
| Nuclear membrane | Lamins, pore proteins | Autoimmune hepatitis, PBC |
